Dual pathway inhibition in patients with coronary artery disease (CAD) in clinical practice in Germany: results from the German CAD subgroup of the XATOA Registry

AimsTo determine characteristics and clinical outcomes of German patients with coronary artery disease (CAD) with or without peripheral artery disease (PAD) who initiated dual pathway inhibition (DPI) using rivaroxaban 2.5 mg twice daily plus aspirin 100 mg once daily in clinical practice in Germany and to compare those with the results for CAD patients of the COMPASS trial.Methods and resultsXATOA was an international prospective registry with a mean follow-up period of 15 months. There were 1641 German CAD patients included, of which 747 patients (45.5%) had CAD only and 894 patients (54.5%) had both CAD and PAD. Baseline characteristics (age, sex, medical history, prior medications) were similar between the subgroups of German CAD patients and comparable to CAD patients of COMPASS. The incidence of major adverse cardiovascular events (MACE) was comparable between CAD patient subgroups of XATOA Germany (only CAD patients: 3.7%, CAD + PAD patients: 3.9%) and was similar to the incidence for CAD patients overall in XATOA and in COMPASS (All CAD patients XATOA: 3.8% vs. 4.2% COMPASS CAD). Incidence for major bleeding was markedly lower in CAD patients of XATOA Germany compared to COMPASS CAD patients (All CAD patients XATOA: 1.1% vs. 3.2% in COMPASS CAD).ConclusionIn this real world experience among German patients with CAD enrolled in XATOA, DPI with rivaroxaban and aspirin was associated with low incidence of MACE and major bleeding.